# Semaglutide: Physician-Grade Research Summaries of the GLP-1 Evidence Base > Semaglutide clinical trial record: STEP, SUSTAIN, SELECT, PIONEER, FLOW, and ESSENCE — every quantitative finding cited. A physician-grade research digest. ## What the semaglutide literature has demonstrated Semaglutide produced mean body weight reduction of 14.9% in adults with obesity over 68 weeks in the STEP 1 trial — roughly six times the 2.4% recorded with placebo in the same study [1]. That headline number comes from a 1,961-person randomized controlled trial published in the New England Journal of Medicine; 86.4% of semaglutide-treated participants achieved at least 5% weight loss versus 31.5% on placebo. Semaglutide is a 31-amino-acid glucagon-like peptide-1 analogue. The molecule differs from endogenous GLP-1 at two key positions: an alpha-aminoisobutyric acid substitution at position 8 confers resistance to DPP-4 enzymatic degradation, and a C18 fatty-diacid side chain attached via a linker at lysine-26 enables greater than 99% albumin binding [8]. The result is a plasma half-life of approximately 165 hours — compared with the 2-minute half-life of native GLP-1 — making once-weekly subcutaneous administration pharmacokinetically feasible. The compound is FDA-approved for three indications as of 2025: type 2 diabetes management (subcutaneous and oral formulations), chronic weight management in adults and adolescents aged 12 and older, and metabolic dysfunction-associated steatohepatitis (MASH, accelerated approval August 2025) [20]. All formulations are prescription-only. The clinical trial program spans more than 50,000 participants across six distinct development programs. Each is summarized in this console. ## What Is Semaglutide? Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the endogenous incretin hormone GLP-1, which is released from intestinal L-cells after nutrient ingestion. GLP-1 receptors are expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, hepatocytes, and cardiovascular tissue; semaglutide activates all of these targets [10]. The compound's molecular weight is 4,113.6 Da. Its sequence shares 94% homology with human GLP-1. Two formulation classes exist. The subcutaneous injectable achieves bioavailability of approximately 89% and Tmax of 24-72 hours [8]. The oral tablet uses SNAC as an absorption enhancer; oral bioavailability is approximately 0.8%, requiring a 14 mg tablet to deliver therapeutically effective plasma concentrations. Oral semaglutide must be taken 30 minutes before the first meal of the day with water only. ## Semaglutide and Obesity Research The STEP program tested semaglutide 2.4 mg subcutaneous once weekly specifically for weight management. STEP 1 enrolled 1,961 adults without diabetes; the 14.9% mean weight loss over 68 weeks was the primary endpoint [1]. STEP 2 enrolled 1,210 adults with coexisting type 2 diabetes and found 9.6% weight loss [4]. STEP 5, a two-year trial in 304 adults, demonstrated that weight loss was sustained: mean 15.2% at week 104 [2]. Body composition data from a DXA substudy of STEP 1 (n=140) showed visceral fat mass reduced by 27.4% and total fat mass by 19.3% at week 68 [11]. ## Cardiovascular Outcomes Semaglutide 2.4 mg reduced MACE by 20% in the SELECT trial (n=17,604; median 39.8 months) in adults with obesity or overweight and established cardiovascular disease but without diabetes [5]. Hazard ratio 0.80 (95% CI 0.72-0.90; p<0.001). SUSTAIN-6 (n=3,297) demonstrated cardiovascular safety with approximately 26% reduction in MACE in patients with type 2 diabetes and high cardiovascular risk over two years [6]. PIONEER 6 confirmed cardiovascular safety for the oral formulation [7]. ## The Six Development Programs - **STEP program**: Eight trials testing 2.4 mg SC for chronic weight management. - **SUSTAIN program**: Nine trials testing SC 0.5-2.0 mg for type 2 diabetes. SUSTAIN-6 provided cardiovascular outcomes certification [6]. SUSTAIN FORTE established 2.0 mg superiority [22]. - **PIONEER program**: Eleven trials testing oral semaglutide for type 2 diabetes. PIONEER 1 established oral efficacy [23]. PIONEER 6 confirmed cardiovascular safety [7]. - **SELECT**: Cardiovascular outcomes in obesity without diabetes (n=17,604) [5]. - **FLOW**: Kidney disease outcomes in T2DM with CKD (n=3,533) [19]. - **ESSENCE**: MASH liver disease resolution outcomes (FDA accelerated approval August 2025) [20]. ## References [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 [2] Garvey WT, Batterham RL, Bhatta M, et al. (STEP 5 Study Group). Two-year effects of semaglutide: the STEP 5 trial. Nat Med. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/ [4] Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract [5] Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 [6] Marso SP et al. SUSTAIN-6. N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 [7] Husain M et al. PIONEER 6. N Engl J Med. 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118 [8] Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/ [10] Papakonstantinou I et al. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/ [11] Wilding JPH et al. Impact of Semaglutide on Body Composition: STEP 1 substudy. J Endocr Soc. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/ [19] Perkovic V et al. FLOW trial. N Engl J Med. 2024;391:109-121. https://www.nejm.org/doi/10.1056/NEJMoa2403347 [20] Sanyal AJ et al. ESSENCE. N Engl J Med. 2025;392(21):2089-2099. https://www.prnewswire.com/news-releases/essence-phase-3-trial-of-semaglutide-showed-significant-improvements-at-72-weeks-in-adults-with-mash-published-in-nejm-302443359.html [22] Rodbard HW et al. SUSTAIN FORTE. Lancet Diabetes Endocrinol. 2021. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00174-1/abstract [23] Aroda VR et al. PIONEER 1. Diabetes Care. 2019;42(9):1724-1732. https://diabetesjournals.org/care/article/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the --- Clinical trial record for one compound — semaglutide — read from the primary sources and indexed here. Not a prescriber, not a vendor.